Business
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and ALS combined Sarasota, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disord
About this update from Oragenics Inc.
[{"type":"image","alt":"Oragenics, Inc.","displaySize":"","headline":null,"caption":"Oragenics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/02a218ac180e2bd4098942c8c71e4535"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EJO5t_9yeEA4D97YiOoXog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/02a218ac180e2bd4098942c8c71e4535","width":300,"height":114}},"lazy":false},{"type":"text","content":"Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy","length":136,"tagName":"p"},{"type":"text","content":"Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and ALS combined","length":148,"tagName":"p"},{"type":"text","content":"Sarasota, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug (IND) readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development. The engagement is intended to align the Company’s upcoming Phase 2a clinical trial in Australia with its U.S regulatory strategy.","length":638,"tagName":"p"},{"type":"text","content":"“We highly value our collaboration with DUCK FLATS Pharma as we advance our IND strategy for ONP-002 and prepare for future U.S. clinical development,” said Janet Huffman, Chief Executive Officer of Oragenics. “By emphasizing regulatory rigor and early preparation, we aim to ensure trial integrity and reduce risk across the U.S. development pathway. DUCK FLATS Pharma’s leadership team has contributed to the development and approval of approximately 40 drug programs, including high-impact intranasal therapies such as Narcan® and neffy®, through regulatory submission strategies, nonclinical and clinical development, and FDA engagement. We believe their experience with market-leading drug programs will meaningfully inform Oragenics’ regulatory and cli...